KIT and prostate carcinoma: Therefore, dasatinib and radotinib may play an important role in the treatment of c-KIT-positive cancers including AML, prostate cancer, etc. In conclusion, these promising data suggest that dasatinib and radotinib are potential target agents for the treatment of c-KIT-positive AML by their regulation of HSP90β activity and expression.